Compulsory Patent Licensing of Drugs in Canada
A Comment on the Debate
Datos Bibliográficos
| ID | 11969284 |
|---|---|
| Autores | Paul K Gorecki (0000-0002-6028-0193, autor de correspondencia), I F Henderson, Ida Henderson |
| Año | 1981 |
| Volumen | 7 |
| Número | 4 |
| Páginas | 559-559 |
| Fecha de publicación | 1981-01-01 |
| Open Access | No |
| Tipo | ARTICLE |
| Revista | Canadian Public Policy (JOURNAL) |
| Identificadores de la revista | ISSN: 0317-0861 • E-ISSN: 1911-9917 |
| Editorial | JSTOR (PUBLISHER) |
| DOI | 10.2307/3549486 |
| OpenAlex | W2090074826 |
| Idioma | EN |
| Citas recibidas | 2 |
| Referencias citadas | 1 |
In 1969 the Patent Act was amended to permit the issuance of licences to import patented drugs. The Pharmaceutical Manufacturers Association of Canada argues that this change has had a minimal impact on retail drug prices while adversely affecting R & D and the balance of trade. A Department of Industry, Trade and Commerce discussion paper released in 1980 on compulsory licensing takes almost the same position as the PMAC. It presents neither independent analysis nor views other than the PMAC's. This article scrutinizes the PMAC case and questions some of their conclusions about the impact of compulsory licensing
Business · Economics · Intellectual property · International trade · Law and economics · Patent law · Political science · Innovation Policy and RD · Intellectual Property and Patents · Law · Pharmaceutical Economics and Policy
| Citas por año | 0,13 |
|---|---|
| Intervalo de citas | 2010 - 2019 (10) |
| Altamente citado | No |